Brief: Dancann Pharma Q4 EBIT Loss Widens To DKK 2.7 Million
26/02/2021 07:26
Feb 26 (Reuters) - Dancann Pharma A/S DANCAN.TE :
* Q4 EBIT LOSS DKK 2.7 MILLION VERSUS LOSS DKK 0.5 MILLION
YEAR
AGO
* THE BOARD OF DIRECTORS AND THE CEO PROPOSE THAT NO
DIVIDEND
SHALL BE PAID FOR THE FISCAL YEAR 2020
Source text for Eikon: ID:nWkr23yxW5
Further company coverage: DANCAN.TE
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Dancann Pharma A/S
See all newsBrief: Dancann Pharma Says Jeppe Krog Rasmussen Resigns As CEO
Brief: Dancann Pharma Says Resolved To Apply For Delisting From Spotlight Stock Market, Subject To Approval By The General Meeting
Brief: Dancann Pharma Says Rights Issue Has Been Subscribed For A Total Of Approximately 77%
Brief: Dancann Pharma A/S Postpones Quarterly Report For Q2 2022
Brief: Dancann Pharma Reports Q1 Net Sales KDKK 1,266 Vs KDKK 874